Biomarkers come in many flavors and can be used as alternatives for assessing the functionality of therapeutics, mechanisms of action, predicting efficacy, monitoring toxicity, and stratification of patient populations. 16 of the 46 (34%) new molecular entities (NME) FDA approved in 2017 had an associated biomarker.
We at KCAS offer several different platforms for biomarker including, MSD, Luminex, SMCxPro, ELISA and flow cytometry. Our experience with a variety of matrices, including plasma, serum, CSF, soft tissues, hard tissues, sputum, and vitreous and aqueous humor enable us to support a wide range of therapeutic areas both non-clinical and clinical.
Clients come to KCAS because we help strategize which biomarkers to multiplex, the platform, and the level of regulation required. We also understand the challenges related to reagent procurement, endogenous levels, data tabulation, and bridging of reagents. Whether it’s for discovery biomarker screening for non-clinical samples or complementary/companion diagnostics for treatment of patients we have got you covered.